$14.64
0.10% today
NYSE, Oct 24, 07:45 pm CET
ISIN
US2561352038
Symbol
RDY

Dr. Reddy's Laboratories Ltd. Sponsored ADR Stock price

$14.62
+0.11 0.76% 1M
+0.94 6.87% 6M
-1.17 7.41% YTD
-1.00 6.38% 1Y
+4.11 39.11% 3Y
+1.16 8.63% 5Y
+1.44 10.93% 10Y
+12.81 708.18% 20Y
NYSE, Closing price Thu, Oct 23 2025
-0.25 1.68%
ISIN
US2561352038
Symbol
RDY
Industry

Key metrics

Basic
Market capitalization
$12.3b
Enterprise Value
-
Net debt
-
Cash
-
Shares outstanding
-
Valuation (TTM | estimate)
P/E
18.7 | 19.3
P/S
3.2 | 3.1
EV/Sales
- | -
EV/FCF
-
P/B
-
Dividends
DPS
$0.09
Yield 1Y | 5Y
0.6% | 0.6%
Growth 1Y | 5Y
-3.9% | 6.5%
Payout 1Y | 3Y
12.4% | 12.4%
Increased
0 Years
Financials (TTM | estimate)
Revenue
$3.8b | $4.0b
EBITDA
$994.6m | $993.9m
EBIT
$789.6m | $779.1m
Net Income
$647.2m | -
Free Cash Flow
-
Growth (TTM | estimate)
Revenue
15.8% | 7.0%
EBITDA
9.2% | 0.1%
EBIT
6.7% | -2.5%
Net Income
2.1% | -
Free Cash Flow
-
Margin (TTM | estimate)
Gross
68.4%
EBITDA
26.1% | 25.0%
EBIT
20.7%
Net
17.0% | -
Free Cash Flow
-
Financial Health
Equity Ratio
67.9%
Return on Equity
16.9%
ROCE
-
ROIC
-
Debt/Equity
-
More
EPS
$0.8
FCF per Share
-
Short interest
2.3%
Employees
27k
Rev per Employee
$140.0k
Show more

Is Dr. Reddy's Laboratories Ltd. Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,040 stocks worldwide.

Dr. Reddy's Laboratories Ltd. Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

45 Analysts have issued a Dr. Reddy's Laboratories Ltd. Sponsored ADR forecast:

13x Buy
29%
14x Hold
31%
18x Sell
40%

Analyst Opinions

45 Analysts have issued a Dr. Reddy's Laboratories Ltd. Sponsored ADR forecast:

Buy
29%
Hold
31%
Sell
40%

Financial data from Dr. Reddy's Laboratories Ltd. Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
3,819 3,819
16% 16%
100%
- Direct Costs 1,208 1,208
25% 25%
32%
2,610 2,610
12% 12%
68%
- Selling and Administrative Expenses 1,132 1,132
21% 21%
30%
- Research and Development Expense - -
-
-
995 995
9% 9%
26%
- Depreciation and Amortization 205 205
20% 20%
5%
EBIT (Operating Income) EBIT 790 790
7% 7%
21%
Net Profit 647 647
2% 2%
17%

In millions USD.

Don't miss a Thing! We will send you all news about Dr. Reddy's Laboratories Ltd. Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Dr. Reddy's Laboratories Ltd. Sponsored ADR Stock News

Positive
Seeking Alpha
18 days ago
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their po...
Neutral
GlobeNewsWire
2 months ago
Extrovis AG Bahnhof Park 46340, Baar, Switzerland Media Relations Contact Madhu Marur madhu.marur@extrovis.com                                          Press Release Extrovis AG and Dr. Reddy's announce the launch of the authorized generic of CARAC (fluorouracil cream), 0.5% in the U.S. Baar, Switzerland; August 14, 2025 Extrovis AG, a global pharmaceutical company focused on research-driven in...
Neutral
Seeking Alpha
3 months ago
Dr. Reddy's Laboratories Limited (NYSE:RDY ) Q1 2026 Earnings Conference Call July 23, 2025 10:00 AM ET Company Participants Erez Israeli - CEO & Member of the Management Council Mannam Venkatanarasimham - CFO & Member of the Management Council Richa Periwal - Head of Investor Relations and Analytics Conference Call Participants Abdulkader Puranwala - ICICI Securities Limited, Research Division...
More Dr. Reddy's Laboratories Ltd. Sponsored ADR News

Company Profile

Dr. Reddy's Laboratories Ltd. engages in the manufacture and marketing of pharmaceutical products. It operates through the following segments: Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others. The Global Generics segment consists of manufacturing and marketing of prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name or as generic finished dosages with therapeutic equivalence to branded formulations. The Pharmaceutical Services and Active Ingredients segment is comprised of manufacturing and marketing of active pharmaceutical ingredients and intermediates, also known as API or bulk drugs, which are principal ingredients for finished pharmaceutical products. The Proprietary Products segment focuses on research, development, and manufacture of differentiated formulations and new chemical entities. The Others segment includes the operations of the wholly-owned subsidiary of the company, Aurigene Discovery Technologies Limited, a discovery stage biotechnology company developing novel and best-in-class therapies in the fields of oncology and inflammation and which works with pharmaceutical and biotechnology companies in early-stage collaborations, brining drug candidates for pre-clinical development. The company was founded by Kallam Anji Reddy on February 24, 1984 and is headquartered in Hyderabad, India.

Head office India
CEO Mr. Israeli
Employees 27,048
Founded 1984
Website www.drreddys.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today